WHO Launches PARTNERS Trial Enrolling BVD Patients to Evaluate MBP134 and Remdesivir

With no approved therapeutics for Bundibugyo virus disease and a confirmed case count exceeding 1,400 in the Democratic Republic of the Congo, WHO has opened patient enrolment in the PARTNERS adaptive platform trial, a development that carries direct implications for biologics manufacturers, CDMOs, and regulatory teams tracking emergency-use frameworks for rare filovirus indications.

The PARTNERS (Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS) trial is evaluating two antiviral candidates: MBP134, a monoclonal antibody, and remdesivir, a small-molecule antiviral already approved for other indications. The trial will also assess whether combination therapy confers additional survival benefit. Both candidates were selected by the WHO Technical Advisory Group following review of preclinical data, safety profiles, and evidence from prior outbreak responses. Enrolled patients receive standardised supportive care per WHO treatment guidelines and are followed for a minimum of 28 days post-enrolment.

The trial's adaptive platform architecture is the operationally significant detail for development and regulatory teams. The design permits additional treatment arms to be added as new candidates clear the Technical Advisory Group's assessment threshold, a structure that compresses the conventional sequential-trial timeline and aligns with accelerated approval principles increasingly referenced in outbreak-response guidance. For CDMOs and biologics manufacturers, the platform model signals that surge-production readiness for investigational monoclonal antibodies must be built into outbreak-response planning before efficacy data are in hand, not after.

Coordination sits with the Institut National de Recherche Biomédicale (INRB) in DRC, the Institute of Tropical Medicine in Belgium, and the University of Oxford, with Africa CDC providing support. The trial is sponsored by WHO and enrolls patients of any age with confirmed BVD diagnosis across participating treatment units in DRC. Of the 1,400-plus confirmed cases recorded since the outbreak began, approximately 440 have been fatal and roughly 210 patients have recovered, figures that underscore both the unmet need and the biological plausibility of intervention.

For regulatory affairs leads, the PARTNERS design offers a live reference point for how adaptive, randomised, controlled trials are being structured under outbreak conditions outside established 21 CFR Part 312 or EMA emergency frameworks, relevant context as agencies continue to refine guidance on platform trials for rare and emerging infectious disease indications. The absence of any approved treatment across all Ebola virus types reinforces that BVD data generated here will not simply fill a gap for one pathogen; it will inform the broader filovirus therapeutic landscape.

The 28-day follow-up endpoint and the trial's stated ambition to generate actionable evidence within months rather than years will serve as a measurable benchmark against which the platform design's operational claims can be assessed.

Source: World Health Organization via WHO News (English), 2 July 2026.